Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal

• Main Authors: Chow, R. (Author), Greer, J.A (Author), Lage, D.E (Author), Nipp, R.D (Author), Sedrak, M.S (Author), Temel, J.S (Author), Williams, G.R (Author)
• Format: Article
• Language: English
• Published: Harborside Press 2022
• Subjects: aged; Aged; antineoplastic agent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; human; Humans; Lung Neoplasms; lung tumor; male; Male; meta analysis; non small cell lung cancer; Progression-Free Survival
• Online Access: View Fulltext in Publisher

 Background: Older adults account for 70% of cancer-related deaths, but previous studies have shown that they are underrepresented in cancer clinical trials. We sought to analyze the representation and outcomes of older adults in trials conducted in the era of novel targeted therapy and immunotherapy. Methods:We searched the 2020 NCCNClinical Practice Guidelines in Oncology and retrieved trials fromthe past 10 years leading to category 1 recommendations in the first-line metastatic setting for the 5 most common causes of cancer death. We categorized trials by cancer type, single-agent versus multiagent approach, and therapeutic class.We described the percentage of older adults (according to each trial's definition) and used a Mantel-Haenszel random-effects meta-analysis model to compare overall and progression-free survival by age. Results:We identified 30 trials consisting of 24,416 patients. Across all trials, 44% of enrolled patients were older adults. Representation of older adults by cancer type within trials was 49% prostate cancer, 38% pancreatic cancer, 37% breast cancer, and 34% non-small cell lung cancer. Representation of older adults also varied by therapeutic class: 20% received immunotherapy, 44% received cytotoxic chemotherapy, 54% received targeted/hormonal therapy, and 34% received combination therapy (P,.001 for all comparisons). For each year since 2010, the percentage of older adults enrolled in trials increased by 1.9%, although this difference was not significant. We observed no difference in overall or progression-free survival between older and younger adults. In our analysis of practice-changing clinical trials, we found that 44% of clinical trial participants were older adults. Trials that included immunotherapy or a combination of therapeutic classes had a lower representation of older adults (,40%). Conclusions:We found that.40% of patients in practice-changing trials are older adults. Although they remain underrepresented in clinical trials compared with the general population, older adults in practice-changing trials seem to be better represented than in previously reported analyses of cooperative group trials. © 2022 Harborside Press. All rights reserved.